Julián Arias-Aponte
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Julián Arias-Aponte has a total of 19 co-authors. Here are the top co-authors by number of shared publications:
- Adriana Rojas-Villarraga
Research Institute, Fundación Universitaria de Ciencias de la salud, Bogotá, Colombia
2 shared publications Laura Villarreal
BIOMAB, Asistential Direction, Bogotá, Colombia
2 shared publications- Paula Daniela Nieto Zambrano
Fundación Universitaria de Ciencias de la Salud
2 shared publications - Pedro Santos-Moreno
Rheumatology Department, Biomab IPS, Bogotá, Colombia
2 shared publications - Arley Gómez López
Fundación Universitaria de Ciencias de la Salud
1 shared publication - Gabriel Esteban Acelas-González
Fundación Universitaria de Ciencias de la Salud, Bogotá, Colombia
1 shared publication
Latest Publications
- Open Access
- 3 November 2026
- Published by Taylor & Francis in Longevity
- Vol. 7 (1)
Association between biological age acceleration and arthritis among older adults in Colombia: a cross-sectional analysis of SABE Colombia
- 3 November 2026
- Published by Taylor & Francis in Longevity
- Vol. 7 (1)
Open AccessAssociation between biological age acceleration and arthritis among older adults in Colombia: a cross-sectional analysis of SABE Colombia
- Open Access
- 31 March 2026
- Published by Journal of Infection in Developing Countries in The Journal of Infection in Developing Countries
- Vol. 20 (03) , 306-317
Comparison of lymphocyte populations, cytokine, and autoantibody profile in patients with rheumatoid arthritis: a study of cases with COVID-19 and controls without COVID-19
Introduction: The SARS-CoV-2 pandemic is associated with the development of acute respiratory distress syndrome (ARDS) and post-COVID syndrome (PCS). PSC has been linked to autoimmune diseases, including rheumatoid arthritis (RA), a condition characterized by chronic joint pain driven by dysregulated immune response. This study aims to evaluate the impact of SARS-CoV-2 infection on patients with RA. Methods: A total of 300 RA patients were included in the study, categorized into two groups: patients with a history of SARS-CoV-2 infection (n = 148) and without prior COVID-19 infection (control group; n = 152). Demographic information, comorbidities, treatments, autoantibodies, cell populations, and cytokines were assessed. Results: A majority of the patients included in this study were female. A high percentage of patients completed the COVID-19 vaccination schedule. The mean age at RA diagnosis was 44.71 years, with most patients presenting with low disease activity. Patients with a history of SARS-CoV-2 infection reported headache, cough, and fatigue more often. A proportion of these symptoms persisted beyond 12 weeks, consistent with PCS. Autoantibody analysis revealed a high seropositivity rate in both groups, with no statistically significant differences related to SARS-CoV-2 infection. Similarly, the evaluation of immune system cell populations showed no significant variations between groups. Cytokine level analysis also demonstrated no statistically significant differences between cases and controls. However, IL-6 data were unavailable for 37% of participants. Conclusions: Long-term follow-up did not demonstrate statistically significant alterations in the immunological profile of RA patients with SARS-CoV-2 infection. Nevertheless, further prospective studies are required to elucidate potential long-term immunological effects in this population.
- 31 March 2026
- Published by Journal of Infection in Developing Countries in The Journal of Infection in Developing Countries
- Vol. 20 (03) , 306-317
Open AccessComparison of lymphocyte populations, cytokine, and autoantibody profile in patients with rheumatoid arthritis: a study of cases with COVID-19 and controls without COVID-19
Introduction: The SARS-CoV-2 pandemic is associated with the development of acute respiratory distress syndrome (ARDS) and post-COVID syndrome (PCS). PSC has been linked to autoimmune diseases, including rheumatoid arthritis (RA), a condition characterized by chronic joint pain driven by dysregulated immune response. This study aims to evaluate the impact of SARS-CoV-2 infection on patients with RA. Methods: A total of 300 RA patients were included in the study, categorized into two groups: patients with a history of SARS-CoV-2 infection (n = 148) and without prior COVID-19 infection (control group; n = 152). Demographic information, comorbidities, treatments, autoantibodies, cell populations, and cytokines were assessed. Results: A majority of the patients included in this study were female. A high percentage of patients completed the COVID-19 vaccination schedule. The mean age at RA diagnosis was 44.71 years, with most patients presenting with low disease activity. Patients with a history of SARS-CoV-2 infection reported headache, cough, and fatigue more often. A proportion of these symptoms persisted beyond 12 weeks, consistent with PCS. Autoantibody analysis revealed a high seropositivity rate in both groups, with no statistically significant differences related to SARS-CoV-2 infection. Similarly, the evaluation of immune system cell populations showed no significant variations between groups. Cytokine level analysis also demonstrated no statistically significant differences between cases and controls. However, IL-6 data were unavailable for 37% of participants. Conclusions: Long-term follow-up did not demonstrate statistically significant alterations in the immunological profile of RA patients with SARS-CoV-2 infection. Nevertheless, further prospective studies are required to elucidate potential long-term immunological effects in this population.
- Open Access
- 3 January 2023
- Published by Elsevier in Journal of Translational Autoimmunity
- Vol. 6, 100187
Polyautoimmunity in systemic lupus erythematosus patients: New insights from a cross-sectional study
- 3 January 2023
- Published by Elsevier in Journal of Translational Autoimmunity
- Vol. 6, 100187
Open AccessPolyautoimmunity in systemic lupus erythematosus patients: New insights from a cross-sectional study